All In Biotech

Drug Trial Radar · NCT07822880

A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

A Phase 4, Single-Arm Study to Evaluate the Safety of Selpercatinib in Participants With RET-Altered Cancers in India

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety of selpercatinib in participants with RET-altered cancers in India. The study will also assess the number of changes and why participants stop study treatment. For each participant, the study is expected to last 56 weeks and will include up to 16 protocol-specific visits.

Conditions

  • Thyroid Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Interventions

  • SelpercatinibDrug

    Tablet administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Treatment Emergent Adverse Event(s) (TEAEs)Time frame: Cycle 1 Day 1, End of Study (approximately 56 weeks) (Cycle = 28 days)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The Gujarat Cancer & Research Institute (GCRI)

    Ahmedabad, India

  • SRV Hospitals

    Bengaluru, India

  • AIIMS, Bhubaneshwar

    Bhubaneswar, India

  • Aadhar Health Institute

    Hisar, India

  • Ruby General Hospital Pvt. Ltd

    Kolkata, India

  • Government Medical College, Kozhikode

    Kozhikode, India

  • Mumbai Oncocare Center

    Mumbai (E), India

  • Institute Rotary Cancer Hospital

    New Delhi, India

  • Vardhman Mahavir Medical College & Safdarjung Hospital

    New Delhi, India

  • MPMMCC(Mahamana Cancer Hospital)

    Varanasi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.